Randomised trials in left main disease: a NOBLE effort

Affiliations

¹ Baylor Scott & White Health, 3110 Allied Drive, Plano, TX 75093, USA. Electronic address: michael.mack@bswhealth.org.
² Mayo Clinic, Rochester, MN, USA.

Comment

Michael Mack et al. Lancet. 2016.

. 2016 Dec 3;388(10061):2715-2716.

doi: 10.1016/S0140-6736(16)32067-0. Epub 2016 Oct 31.

¹ Baylor Scott & White Health, 3110 Allied Drive, Plano, TX 75093, USA. Electronic address: michael.mack@bswhealth.org.
² Mayo Clinic, Rochester, MN, USA.

No abstract available

Comment on

Percutaneous coronary angioplasty versus coronary artery bypass grafting in treatment of unprotected left main stenosis (NOBLE): a prospective, randomised, open-label, non-inferiority trial.
Mäkikallio T, Holm NR, Lindsay M, Spence MS, Erglis A, Menown IB, Trovik T, Eskola M, Romppanen H, Kellerth T, Ravkilde J, Jensen LO, Kalinauskas G, Linder RB, Pentikainen M, Hervold A, Banning A, Zaman A, Cotton J, Eriksen E, Margus S, Sørensen HT, Nielsen PH, Niemelä M, Kervinen K, Lassen JF, Maeng M, Oldroyd K, Berg G, Walsh SJ, Hanratty CG, Kumsars I, Stradins P, Steigen TK, Fröbert O, Graham AN, Endresen PC, Corbascio M, Kajander O, Trivedi U, Hartikainen J, Anttila V, Hildick-Smith D, Thuesen L, Christiansen EH; NOBLE study investigators. Mäkikallio T, et al. Lancet. 2016 Dec 3;388(10061):2743-2752. doi: 10.1016/S0140-6736(16)32052-9. Epub 2016 Oct 31. Lancet. 2016. PMID: 27810312 Clinical Trial.